NVAX

Business Context and Reporting Period

Company: NOVAVAX INC
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2007
Business Overview: Novavax is a biopharmaceutical company focused on developing vaccines using proprietary virus-like particle (VLP) technology and a micellar nanoparticle (MNP) drug delivery platform. Key product candidates include vaccines for H5N1 avian influenza and the FDA-approved estrogen replacement product ESTRASORB.

Key Financial Metrics

Note: Figures in thousands. Working capital calculated as Total Current Assets ($63,480) minus Total Current Liabilities ($5,645).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues for the six months ended June 30, 2007, decreased by 61% ($1.3 million) compared to the prior year. This was driven by a 73% drop in product sales (due to the discontinuation of Gynodiol and lower ESTRASORB shipments) and a 62% drop in contract research revenues.
• Increased Operating Expenses: Operating costs rose 30% year-over-year for the six-month period. Research and Development (R&D) expenses increased 45% to $7.9 million due to expanded preclinical testing for influenza vaccine candidates. Selling, General, and Administrative (SG&A) expenses increased 47% to $8.0 million, partly due to $1.0 million in reserves for notes receivable from former directors and costs associated with a new facility in Rockville, Maryland.
• Widened Net Loss: Net loss increased by 39% to $16.6 million for the six-month period, primarily due to lower revenues and higher operating expenses, partially offset by higher net interest income.
• Inventory Write-downs: The company recorded $560,000 in excess inventory costs over market value for ESTRASORB during the six months ended June 30, 2007, as the product is sold below manufacturing cost.

Guidance, Outlook, and Risks

• Clinical Progress: On July 31, 2007, the company began Phase I/IIa clinical trials for its H5N1 pandemic influenza vaccine.
• Liquidity Outlook: Management believes current cash resources ($61.2 million) are sufficient to sustain operations into late 2008 without new financing. However, future capital requirements depend on R&D progress and regulatory approvals.
• Debt Amendments: On June 15, 2007, the company amended its $22 million convertible notes, lowering the conversion price from $5.46 to $4.00 per share and mandating conversion if the stock price exceeds $7.00 for 15 of 30 consecutive trading days after July 19, 2007.
• Key Risks:
  • Manufacturing Losses: ESTRASORB continues to be manufactured at a loss; profitability depends on negotiating third-party manufacturing or increasing volumes.
  • Regulatory Uncertainty: No assurance that vaccine candidates will receive regulatory approval or be commercially viable.
  • Related Party Receivables: Significant reserves ($1.1 million total) were established for notes receivable from two former directors due to declining stock prices reducing the value of pledged collateral.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $12.6 million operating cash outflow over six months against the $61.2 million cash balance.
• Convertible Note Terms: Confirm the impact of the amended conversion price ($4.00) and mandatory conversion trigger ($7.00) on potential future dilution.
• ESTRASORB Economics: Assess the timeline and feasibility of transitioning ESTRASORB manufacturing to a third party to stop operating losses on the product.
• Director Notes: Review the recoverability of the $1.3 million in notes receivable from former directors, given the existing reserves and stock price volatility.
• R&D Milestones: Monitor the results of the Phase I/IIa H5N1 vaccine trials initiated in late July 2007.